At ASCO, Pfizer Presents Data on New Mutation-Targeting NSCLC Drug | GenomeWeb

ORLANDO, Fla. — An investigational drug developed by Pfizer to selectively attack certain genetic features of non-small cell lung cancer cells was able to stop or shrink tumor growth in a majority of patients enrolled in an early study, according to an abstract presented at the American Society of Clinical Oncology's annual meeting here this weekend.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.